Latest Breaking News On - Pivotal study - Page 16 : comparemela.com

Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual Meeting The posters highlight the company s progress with Zygel, a CBD-based gel for use as a therapy for Fragile X Syndrome Both posters will be made available on the Zynerba corporate website at http://zynerba.com/publications/ Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting.  Both posters will be made available on the Zynerba corporate website. The first poster titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]” describes responder thresholds representing individual patient-level changes that the company believes are indicative of meaningful treatment be

Josephm palumboSociety of biological psychiatryDrug administrationBiological psychiatryFragilex syndromeProposed mechanismTranslates into meaningful clinical benefitsPivotal studyTransdermal gelAdolescents with fragilex syndromePoster sessionசமூகம் ஆஃப் உயிரியல் மனநல மருத்துவம்உயிரியல் மனநல மருத்துவம்ப்ரபோஸ்ட் பொறிமுறைமுக்கிய படிப்புபோஸ்டர் அமர்வு